Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3

Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3

Familial hemophagocytic lymphohistiocytosis (FHL) is a rare and fatal autosomal recessive immune disorder characterized by uncontrolled activation of T and NK cells, macrophages, and overproduction of inflammatory cytokines. Early hematopoietic cell transplantation (HCT) is required for long-term su...

Full description

Bibliographic Details
Main Authors: Daiki Niizato, Takeshi Isoda, Noriko Mitsuiki, Shuya Kaneko, Dan Tomomasa, Takahiro Kamiya, Masatoshi Takagi, Kohsuke Imai, Michiko Kajiwara, Masaki Shimizu, Tomohiro Morio, Hirokazu Kanegane
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Immunology
Subjects:
cytokine
familial hemophagocytic lymphohistiocytosis (FHL)
HLH
hematopoietic cell transplantation (HCT)
janus kinase
ruxolitinib
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.977463/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.977463/full

Similar Items